NRI

(redirected from Norepinephrine reuptake inhibitor)
Also found in: Medical, Wikipedia.
AcronymDefinition
NRINon-Resident Indian
NRINational Resources Inventory
NRINomura Research Institute (Tokyo, Japan)
NRINatural Resources Institute
NRINational Rejectors, Inc. (various locations)
NRINorepinephrine Reuptake Inhibitor (psychopharmacology)
NRINational Research Initiative (USDA)
NRINon-Resident Importer
NRINetworked Readiness Index
NRINuvo Research, Inc. (Canada)
NRINational Research Institute
NRINatural Resources Inventory
NRINet Revenue Interest
NRINanosystem Research Institute (Japan)
NRINASMHPD Research Institute
NRINanoelectronics Research Initiative
NRINegative Refractive Index
NRINon-Resident International (various organizations)
NRINon-Roster Invitee (baseball)
NRINunavut Research Institute
NRINot Really Interested
NRINippon Research Institute (Japan)
NRINet Radio Interface
NRINet Resources International
NRINon-Returning-Indian
NRINon Residential Indian
NRINeural Response Imaging (audiology)
NRINetwork of Relationships Inventory (psychology)
NRINonwovens Report International (textile magazine)
NRINetwork Resource Identifier (3GPP)
NRINon Recurring Item (finance)
NRINorthern Realities, Inc.
NRINational Recovery Institutes
NRINominal Ranging Interval
NRINet Radio Interference
NRINational Remembrance Institute
NRINormalized Reliability Importance
NRINonrecurring Investment
NRINorris Rentals, Inc
NRINon-Repairable Item
NRINational Republic of Iran
References in periodicals archive ?
Atomoxetine is a highly selective norepinephrine reuptake inhibitor recently approved for the treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder (ADHD) (46, 47).
AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor that has the potential to address the key symptoms of narcolepsy.
27, 2018 (HealthDay News) -- A low risk of serotonin syndrome is seen in association with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, according to a study published online Feb.
Strattera, a selective norepinephrine reuptake inhibitor, is approved for both pediatric and adult patients.
Reboxetine (a-ariloxybenzyl derivative of morpholine) is a norepinephrine reuptake inhibitor and also a norepinephrine transporter inhibitor, indicated in the therapy of unipolar depression, in panic and attention deficit hyperactivity disorders (4).
The drug, a selective serotonin norepinephrine reuptake inhibitor (SNRI), has already been shown to be effective in relieving this bothersome menopausal symptom in a 12-week trial, which was reported last year.
Jazz Pharmaceuticals said solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for the treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.
Esbupropion is the S-enantiomer of bupropion, a dopamine and norepinephrine reuptake inhibitor and nicotinic acetylcholine receptor antagonist which also serves to increase the bioavailability of dextromethorphan.
Children and adolescents with attention-deficit hyperactivity disorder who are resistant to methylphenidate showed significant improvement in their ADHD symptoms while taking reboxetine, a selective norepinephrine reuptake inhibitor, said Sharon Ratner, M.D., of the Tel Aviv-Brull Community Mental Health Center and her colleagues.
It was reported yesterday that United States-based Sunovion Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration for dasotraline, a novel investigational, dual-acting dopamine and norepinephrine reuptake inhibitor.
Dasotraline is a new chemical entity that acts as a dual dopamine and norepinephrine reuptake inhibitor. It has an extended half-life (47-77 hours) that supports the potential for stable plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.
Sumitomo Dainippon Pharma Co Ltd, a Japan-based pharmaceutical company, on Wednesday announced positive topline results from a Phase 3 study evaluating the novel drug candidate dasotraline (generic name, code name: SEP-225289), a dopamine norepinephrine reuptake inhibitor, being evaluated in children ages 6 to 12 years with attention deficit hyperactivity disorder (ADHD).